At 12.5% CAGR, South & Central America Upstream Bioprocessing Market s Projected to be Worth US$ 981.89 Million by 2030, says Business Market Insights.

According to Business Market Insights’ research, the South & Central America upstream bioprocessing market was valued at US$ 382.56 million in 2022 and is expected to reach US$ 981.89 million by 2030, registering a CAGR of 12.5% from 2022 to 2030. Increasing investments in R&D in biopharmaceutical industry and rapid growth of pharmaceutical and biotechnology industries are among the critical factors attributed to the South & Central America upstream bioprocessing market expansion.             

Increasing investments in research and development (R&D) in the biopharmaceutical industry are likely to bring new trends into the upstream bioprocessing market in the coming years. In March 2020, Culture Biosciences announced securing the funds of US$ 15 million (€13.4 million) in the Series A investment round, citing the backing of new and existing venture capital backers. According to Culture Biosciences, the money has been used to treble the capacity of bioreactors as well as to develop more cloud-based software monitoring and development tools for biomanufacturing research and development. The company states that this investment will help scientists manage their whole R&D workflow via software applications, hence supporting the digitization of biomanufacturing R&D.

As R&D investments continue to surge, particularly in novel biologics, advanced therapies, and personalized medicine, there is a parallel emphasis on optimizing upstream bioprocessing technologies and methodologies. This trend is leading to the development of innovative bioreactor systems, cell culture media formulations, and process automation solutions to enhance the efficiency, scalability, and productivity of biopharmaceutical production operations. Furthermore, the focus on R&D investments favors the development of cutting-edge bioprocessing platforms that cater to the evolving landscape of biopharmaceuticals, including next-generation therapeutic modalities and biosimilars. Additionally, dedicating R&D funds for bioprocessing trends such as continuous bioprocessing and advanced analytics for process monitoring is expected to reshape the future of upstream bioprocessing, driving the adoption of state-of-the-art technologies and establishing new benchmarks for process performance, quality, and regulatory compliance.

On the contrary, stringent regulatory framework hampers the growth of South & Central America upstream bioprocessing market.

Based on product type, the South & Central America upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters segment held 35.2% market share in 2022, amassing US$ 134.60 million. It is projected to garner US$ 342.96 million by 2030 to expand at 12.4% CAGR during 2022–2030.

Based on workflow, the South & Central America upstream bioprocessing market is segmented into media preparation, cell culture, and cell separation. The cell separation segment held 41.9% share of South & Central America upstream bioprocessing market in 2022, amassing US$ 160.27 million. It is projected to garner US$ 426.49 million by 2030 to expand at 13.0% CAGR during 2022–2030.

By usage type, the South & Central America upstream bioprocessing market is bifurcated into single-use and multi-use. The single-use segment held 54.3% share of South & Central America upstream bioprocessing market in 2022, amassing US$ 207.54 million. It is projected to garner US$ 542.00 million by 2030 to expand at 12.7% CAGR during 2022–2030.

In terms of mode, the South & Central America upstream bioprocessing market is bifurcated into In-house and outsourced. The In-house segment held 62.5% share of South & Central America upstream bioprocessing market in 2022, amassing US$ 239.23 million. It is projected to garner US$ 603.04 million by 2030 to expand at 12.3% CAGR during 2022–2030.

Based on country, the South & Central America upstream bioprocessing market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 65.3% share of South & Central America upstream bioprocessing market in 2022. It was assessed at US$ 249.89 million in 2022 and is likely to hit US$ 654.80 million by 2030, exhibiting a CAGR of 12.8% during 2022–2030.            

Key players operating in the South & Central America upstream bioprocessing market are Thermo Fisher Scientific Inc, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, and Corning Inc, among others.

• In December 2023, Merck has acquired Erbi Biosystems, a Massachusetts-based company that developed the "Breez" 2 ml micro-bioreactor platform technology. Merck's upstream therapeutic protein portfolio is boosted by the purchase, enabling it to promptly develop lab-scale protocols for scalable cell-based perfusion bioreactor processes with capacities ranging from 2 ml to 2000 l. Additionally, it offers opportunities for further study and advancement in cutting-edge modality applications, like cell therapies.
• In May 2023, Danaher Corp announced that it has merged its Pall portfolio under the Cytiva brand. The merger has enhanced customers' access to bioprocess technologies and services. The merger will help the company offer biomanufacturers products and technologies across the full bioprocess spectrum, ranging from cell culture to drug products. All the products will be sold under the brand Cytiva. In addition, the merger has combined iCELLis, Kleenpak, Allegro, Supor, and Pegasus, in addition to ÄKTA, Amersham, B Sefia, Whatman, Xcellerex, Xuri, Biacore, FlexFactory, HyClone, and MabSelect.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com